Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.
Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges
Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market.
Sun Pharma Q4 PAT jumps 26% YoY to Rs 2,714 cr
Sun Pharmaceutical Industries has reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago.
Sun Pharma Q4 Results: Profit Jumps 26% Even As Margins Slip; Dividend Declared
Sun Pharma registered exceptional gains worth approximately Rs 1,700 crore in fiscal 2026.
Q4 Results Live Updates: Sun Pharma Revenue Up 12%; IRCON Profit Falls 10%
Key companies in focus include Sun Pharma, NTPC Green Energy, Hindalco Industries, Eicher Motors, Colgate-Palmolive (India), Fortis Healthcare and 3M India.
Sensex today | Stock Market Live: Sensex drops day's gain, Nifty near 23,700; Max Health, Sun Pharma top losers - BusinessLine
Sensex today | Stock Market Live: Sensex drops day's gain, Nifty near 23,700; Max Health, Sun Pharma top losersBusinessLine
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Sun Pharma Q4 results 2026: Profit jumps 26% YoY to ₹2,714 crore; recommends final dividend of ₹5 for FY26
Sun Pharma Q4 results 2026: Profit jumped 26% YoY to ₹2,714 crore. Total revenue from operations for the quarter under review rose 12.8% YoY to ₹14,611.79 crore. Sun Pharma's board recommended a final dividend of ₹5 per share of ₹l each.
Q4 Results LIVE Updates: Max Health shares decline 7%, Honasa Consumer up 7%; Hindalco report today
Q4 Results Live Update: Another busy earnings week ends with three Nifty names - Sun Pharma, Eicher Motors and Hindalco reporting their results today, along with broader market names like Torrent Pharma, Fortis Healthcare, DAM Capital, Colgate-Palmolive, IRCON International, Jubilant Pharmova, Minda Corp, and many others. LG, LIC, GAIL, ITC, will also be reacting to their results reported on Thursday.
Stocks to watch: Sun Pharma, Hindalco, ITC, Maruti Suzuki among 10 shares in focus today; check list here - Mint
Stocks to watch: Sun Pharma, Hindalco, ITC, Maruti Suzuki among 10 shares in focus today; check list hereMint
Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments Bank
Benchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to continue its consolidation between 23,200 and 23,900. Several companies, including ITC, LIC, Sun Pharma, Maruti Suzuki, and Fino Payments Bank, are in focus due to Q4 results and other developments.